London
· Delayed Price · Currency is GBP · Price in USD Xeris Biopharma Holdings Company Description
Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies in Illinois.
The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome.
It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase I clinical trial for the treatment of hypothyroidism; and non-aqueous XeriSol and XeriJect technologies for various therapies.
The company was incorporated in 2005 and is headquartered in Chicago, Illinois.
| Country | United States |
| Founded | 2005 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 377 |
| CEO | John Shannon |
Contact Details
Address: 180 North LaSalle Street Chicago, Delaware 60601 United States | |
| Phone | 844 445 5704 |
| Website | xerispharma.com |
Stock Details
| Ticker Symbol | 0A8E |
| Exchange | London Stock Exchange |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| ISIN Number | US98422E1038 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| John Shannon | Chief Executive Officer |
| Steven Pieper | Chief Financial Officer |
| Allison Wey | Head of Investor Relations |